Regulation of apoptosis in prostate cancer

Cancer and Metastasis Reviews

Volumn 20, Issue 3-4, 2001, Pages 225-243

  Gurumurthy, Sushma ^a   Murthi Vasudevan, Krishna ^a   Rangnekar, Vivek M ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Genes; Prostate cancer

Indexed keywords

CAVEOLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 4; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; APOPTOSIS; CALCIUM CELL LEVEL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; EPITHELIUM CELL; GENETIC REGULATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

APOPTOSIS; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 0035740627     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015583310759     Document Type: Review

References (132)

1. Proliferation, cell cycle and apoptosis in cancer
2. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-beta 1 and bcl- 2 expression
3. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
4. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes
5. Hormone-refractory prostate cancer: An evolving standard of care
6. Androgen regulation of programmed death of normal and malignant prostatic cells
7. p53 and bcl- 2 immunohistochemical alterations in prostate cancer treated with radiation therapy
8. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer
9. Apoptotic pathways in prostate cancer
10. The biochemistry of apoptosis
11. Four deaths and a funeral: From caspases to alternative mechanisms
12. Caspases: Enemies within
13. The phosphatidylserine receptor: A crucial molecular switch?
14. Fas-mediated apoptosis in human prostatic carcinoma cell lines
15. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression
16. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin
17. Programmed death of nonproliferating androgen-independent prostatic cancer cells
18. Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells
19. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin
20. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells
21. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
22. The role of calcium in the regulation of apoptosis
23. Induction of a caspase-3-like activity by calcium in normal cytosolic extracts triggers nuclear apoptosis in a cell-free system
24. BCL-2 family members and the mitochondria in apoptosis
25. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax
26. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax
27. XL and Bcl-2, displaces Bax and promotes cell death
28. Bcl-2 and Bax function independently to regulate cell death
29. Oncogenic potential of bcl-2 demonstrated by gene transfer
30. Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity
31. Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes
32. XL regulates the membrane potential and volume homeostasis of mitochondria
33. XL inhibits Ara-C-induced mitochondrial loss of cytochrome C and other perturbations that activate the molecular cascade of apoptosis
34. The release of cytochrome C from mitochondria: A primary site for Bcl-2 regulation of apoptosis
35. Prevention of apoptosis by Bcl-2: Release of cytochrome C from mitochondria blocked
36. XL regulates apoptosis by heterodimerization-dependent and -independent mechanisms
37. XL has activity independent of cytochrome C release
38. XL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells
39. 2+
40. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer
41. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
42. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
43. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
44. Expression of bcl-2 and the progression of human and rodent prostatic cancers
45. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis
46. Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation
47. XL underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells
48. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
49. The transcription factor NF-κB: Control of oncogenesis and cancer therapy resistance
50. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis
51. Constitutive activation of IκB kinase alpha and NF-κB in prostate cancer cells is inhibited by ibuprofen
52. Aberrant rel/NF-κB genes and activity in human cancer
53. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice
54. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
55. Transcriptional cross talk between NF-κB and p53
56. Inhibition of NFκB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter
57. p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP
58. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells
59. Activation of NF-κB by antineoplastic agents. Role of protein kinase C
60. The role of constitutive NF-κB activity in PC-3 human prostate cancer cell invasive behavior
61. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation
62. The contradictions of the insulin-like growth factor 1 receptor
63. Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd 4
64. Molecular markers of IGF-I-mediated mitogenesis
65. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study
66. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
67. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds
68. The IGF-I receptor in cancer research
69. Caveolins, liquid-ordered domains, and signal transduction
70. Role of plasmalemmal caveolae in signal transduction
71. Caveolin-1, a putative tumour suppressor gene
72. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis
73. Elevated expression of caveolin is associated with prostate and breast cancer
74. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells
75. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation
76. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells
77. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells
78. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
79. Akt is more than just a bad kinase
80. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon
81. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor
82. Pro-survival function of akt/protein kinase b in prostate cancer cells. Relationship with trail resistance
83. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state
84. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
85. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN
86. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
87. Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10
88. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity
89. p53: Death star
90. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function
91. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
92. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer
93. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells
94. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation
95. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells
96. Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1
97. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
98. p63 is a prostate basal cell marker and is required for prostate development
99. p63 protein expression is rare in prostate adenocarcinoma: Implications for cancer diagnosis and carcinogenesis
100. p73 is a human p53-related protein that can induce apoptosis
101. Mutation and expression analysis of the p73 gene in prostate cancer
102. Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma
103. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms
104. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor
105. Bin1 mediates apoptosis by c-Myc in transformed primary cells
106. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma
107. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program
108. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target
109. Mechanisms of TGF-beta-induced cell cycle arrest
110. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells
111. Apoptosis is induced by transforming growth factor-beta 1 within 5 hours in regressing liver without significant fragmentation of the DNA
112. Growth factor involvement in progression of prostate cancer
113. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate
114. Transforming growth factor-beta 1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium
115. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens
116. Transforming growth factor-beta and prostate cancer
117. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro
118. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-beta type II dominant negative receptor
119. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis
120. SMAD3 represses androgen receptor-mediated transcription
121. Expression and function of the leucine zipper protein Par-4 in apoptosis
122. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C
123. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1
124. Interaction partners of DIk/ZIP kinase: Co-expression of DIk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis
125. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation
126. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression
127. Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade
128. Oncogenic Ras sensitizes cells to apoptosis by Par-4
129. Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis
130. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues
131. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4
132. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis